一分钟看懂
这是一项关于肺癌的II 期研究，登记的药物或干预包括Sunvozertinib；Crizotinib；Pralsetinib；Larotrectinib；Savolitinib；Pyrotinib；Dabrafenib+Trametinib；Glecirasib；Ensartinib，当前状态为招募中。登记地点显示中国广州有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Sunvozertinib；Crizotinib；Pralsetinib；Larotrectinib；Savolitinib；Pyrotinib；Dabrafenib+Trametinib；Glecirasib；Ensartinib · II 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Sun Yat-sen University Cancer Center · 广州
公开的入选条件
- * Subjects must have treatment-naive unresectable stage III NSCLC according to the AJCC 8th edition staging;
- * Squamous or non-squamous NSCLC histology;
- * Subjects should have a rare mutation based on NGS, including mutations of EGFR exon20ins, ROS1 fusion, RET fusion, NTRK fusion, MET 14 exon, HER2, BRAF V600E, KRAS G12C, and ALK fusion.
- * Subjects should be without EGFR exon 19 deletions or exon 21 L858R activating mutation;
- * Male and female, aged 18-75 years;
- * Blood and specimens before and after treatment must be provided;
- * Eastern Cooperative Oncology Group (ECOG) performance status of 0-1;
- * Adequate hematological function: Absolute neutrophil count (ANC) ≥2.0 x 109/L, and Platelet count ≥100 x 109/L, and Hemoglobin ≥9 g/dL (may be transfused to maintain or exceed this level);
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT06563999；登记信息更新于 2026-04-21。